Approaches for suppression of statins-induced rhabdomyolysis

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K18877
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Pharmacology in pharmacy
• Research Institution: Meiji Pharmaceutical University
• Principal Investigator: Araki Makoto 明治薬科大学, 薬学部, 助教 (20552904)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: スタチン / 横紋筋融解症 / オートファジー

Outline of Final Research Achievements

Statins, inhibitor of the rate-limiting enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase for synthesis of cholesterol, are used for the therapy for hypercholesterolemia. On the other hand, statins cause rhabdomyolysis of side effects. We aim to elucidate the mechanism of side effect and establish inhibitory method for statin-induced rhabdomyolysis. In this study,　a series of compounds was screened to identify inhibitor for statin-induced autophagy. Unfortunately, we were not able to identify the specific compounds, but achieve positive results suggested that small G proteins are involved in statin-induced autophagy. We expect that elucidation of the molecular mechanisms of statin-induced autophagy is available for suppression for side effect of statins.

Free Research Field

薬学